Compare BHR & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHR | STXS |
|---|---|---|
| Founded | 2013 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.6M | 210.0M |
| IPO Year | N/A | 2004 |
| Metric | BHR | STXS |
|---|---|---|
| Price | $2.87 | $2.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 788.3K | 388.9K |
| Earning Date | 02-25-2026 | 11-11-2025 |
| Dividend Yield | ★ 7.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $710,399,000.00 | $30,075,000.00 |
| Revenue This Year | N/A | $24.21 |
| Revenue Next Year | N/A | $29.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.62 |
| 52 Week Low | $1.80 | $1.54 |
| 52 Week High | $3.28 | $3.59 |
| Indicator | BHR | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 56.65 |
| Support Level | $2.77 | $2.25 |
| Resistance Level | $2.88 | $2.48 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 50.24 | 48.94 |
Braemar Hotels & Resorts Inc is a real estate investment trust company that invests in high revenue per available room, or RevPAR, luxury, upper-upscale and upscale hotels in gateway and resort locations. The firm operates in various U.S. states such as California, Texas, Washington, Philadelphia, Florida, and Illinois as well as Washington, D.C. and St. Thomas, U.S. Virgin Islands. The company operates through its direct hotel investment segment of the hotel lodging industry. Its revenue streams include rooms, food and beverage, and other. The firm's hotels operate under various brands, such as Marriott, Hilton, Courtyard, and, among others.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.